258 related articles for article (PubMed ID: 23103087)
1. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Seki JT; Banglawala S; Lentz EM; Reece DE
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
[No Abstract] [Full Text] [Related]
2. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
3. Desensitization to thalidomide in a patient with multiple myeloma.
Nucera E; Schiavino D; Hohaus S; Leone G; Buonomo A; Lombardo C; Patriarca G
Clin Lymphoma Myeloma; 2008 Jun; 8(3):176-8. PubMed ID: 18650182
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
5. [Desensitization to lenalidomide].
Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
[No Abstract] [Full Text] [Related]
6. Successful desensitization in a patient with lenalidomide hypersensitivity.
Phillips J; Kujawa J; Davis-Lorton M; Hindenburg A
Am J Hematol; 2007 Nov; 82(11):1030. PubMed ID: 17617781
[No Abstract] [Full Text] [Related]
7. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
[No Abstract] [Full Text] [Related]
9. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
10. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Morita Y; Shimada T; Yamaguchi T; Rai S; Hirase C; Emoto M; Serizawa K; Taniguchi Y; Ojima M; Tatsumi Y; Ashida T; Matsumura I
Int J Hematol; 2011 Dec; 94(6):583-4. PubMed ID: 22127558
[No Abstract] [Full Text] [Related]
11. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Tannemaat MR; Vries EP; Molendijk WJ; Haan J
Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
[No Abstract] [Full Text] [Related]
12. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF
Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571
[No Abstract] [Full Text] [Related]
13. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
14. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
15. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
16. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Dasanu CA; Alexandrescu DT
Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
[TBL] [Abstract][Full Text] [Related]
17. A case of lenalidomide-induced hypersensitivity pneumonitis.
Lerch E; Györik S; Feilchenfeldt J; Mazzucchelli L; Quadri F
Onkologie; 2010; 33(5):249-52. PubMed ID: 20502059
[TBL] [Abstract][Full Text] [Related]
18. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
19. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide-induced hypersensitivity pneumonitis.
Kortuem M; Einsele H
Onkologie; 2010; 33(5):219. PubMed ID: 20502054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
